Efficacy of edelfosine lipid nanoparticles in breast cancer cells

International Journal of Pharmaceutics

Volumn 454, Issue 2, 2013, Pages 720-726

  Aznar, María Ángela ^a   Lasa Saracíbar, Beatriz ^a   De Mendoza, Ander Estella Hermoso ^a,b   Blanco Prieto, María José ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b ETH ZURICH   (Switzerland)

Author keywords

Alkylphospholipids; Breast cancer; Edelfosine; Lipid nanoparticles; MCF7

Indexed keywords

EDELFOSINE; GLYCEROL PALMITOSTEARATE; LIPOSOME;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL;

ALKYLPHOSPHOLIPIDS; ALPS; B-LN; BLANK (UNLOADED) NANOPARTICLES; BREAST CANCER; EDELFOSINE; EDELFOSINE-LOADED LIPID NANOPARTICLES; ENHANCED PERMEABILITY AND RETENTION EFFECT; EPR EFFECT; ET; ET-LN; IC(50); INHIBITORY CONCENTRATION 50; LIPID NANOPARTICLES; LN; MANTLE CELL LYMPHOMA; MCF7; MCL; PDI; PI; POLYDISPERSITY INDEX; PROPIDIUM IODIDE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL SURVIVAL; DIGLYCERIDES; FEMALE; HUMANS; MCF-7 CELLS; NANOPARTICLES; PHOSPHOLIPID ETHERS; POLYSORBATES;

EID: 84884140318     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.04.068     Document Type: Article

References (42)

1. Ahmad, I., Filep, J.J., Franklin, J.C., Janoff, A.S., Masters, G.R., Pattassery, J., Peters, A., Schupsky, J.J., Zha, Y., Mayhew, E., 1997. Enhanced therapeutic effects of liposome-associated 1-O-octadecyl-2-O-methyl-sn-glycero- 3-phosphocholine. Cancer Res. 57, 1915-1921. (Pubitemid 27209721)
2. Anton, N., Benoit, J.P., Saulnier, P., 2008. Design and production of nanoparticles formulated from nano-emulsion templates - a review. J. Control. Release 128, 185-199.
3. Brannon-Peppas, L., Blanchette, J.O., 2004. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56, 1649-1659. (Pubitemid 39177694)
4. Charman, W.N., Stella, V.J. (Eds.), 1992. Lymphatic Transport of Drugs. CRC Press, Boca Raton.
5. Clogston, J.D., Patri, A.K., 2011. Zeta potential measurement. Methods Mol. Biol. 697, 63-70.
6. Darzynkiewicz, Z., Bedner, E., Smolewski, P., 2001. Flow cytometry in analysis of cell cycle and apoptosis. Semin. Hematol. 38, 179-193. (Pubitemid 32319316)
7. Estella-Hermoso de Mendoza, A., Campanero, M.A., de la Iglesia-Vicente, J., Gajate, C., Mollinedo, F., Blanco-Prieto, M.J., 2009a. Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice. Clin. Cancer Res. 15, 858-864.
8. Estella-Hermoso de Mendoza, A., Campanero, M.A., Lana, H., Villa-Pulgarin, J.A., de la Iglesia-Vicente, J., Mollinedo, F., Blanco-Prieto, M.J., 2012. Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles. Nanomedicine (Lond) 7, 679-690.
9. Estella-Hermoso de Mendoza, A., Campanero, M.A., Mollinedo, F., Blanco-Prieto, M.J., 2009b. Comparative study of A HPLC-MS assay versus an UHPLC-MS/MS for anti-tumoral alkyl lysophospholipid edelfosine determination in both biological samples and in lipid nanoparticulate systems. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 877, 4035-4041.
10. Estella-Hermoso de Mendoza, A., Campanero, M.A., Mollinedo, F., Blanco-Prieto, M.J., 2009c. Lipid nanomedicines for anticancer drug therapy. J. Biomed. Nanotechnol. 5, 323-343.
11. Estella-Hermoso de Mendoza, A., Preat, V., Mollinedo, F., Blanco-Prieto, M.J., 2011. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J. Control. Release 156, 421-426.
12. Estella-Hermoso de Mendoza, A., Rayo, M., Mollinedo, F., Blanco-Prieto, M.J., 2008. Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: development and in vitro characterization. Eur. J. Pharm. Biopharm. 68, 207-213.
13. Gajate, C., Gonzalez-Camacho, F., Mollinedo, F., 2009. Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. PLoS ONE 4, e5044.
14. Gajate, C., Mollinedo, F., 2007. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 109, 711-719. (Pubitemid 46105973)
15. Gajate, C., Santos-Beneit, A.M., Macho, A., Lazaro, M., Hernandez-De Rojas, A., Modolell, M., Munoz, E., Mollinedo, F., 2000. Involvement of mitochondria and caspase-3 in ET-18-OCH(3)-induced apoptosis of human leukemic cells. Int. J. Cancer 86, 208-218. (Pubitemid 30180816)
16. Houlihan, W.J., Lohmeyer, M., Workman, P., Cheon, S.H., 1995. Phospholipid antitumor agents. Med. Res. Rev. 15, 157-223.
17. Kaszuba, M., Corbett, J., Watson, F.M., Jones, A., 2010. High-concentration zeta potential measurements using light-scattering techniques. Philos. Transact. A Math. Phys. Eng. Sci. 368, 4439-4451.
18. Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E.S., Baehrecke, E.H., Blagosklonny, M.V., El-Deiry, W.S., Golstein, P., Green, D.R., Hengartner, M., Knight, R.A., Kumar, S., Lipton, S.A., Malorni, W., Nunez, G., Peter, M.E., Tschopp, J., Yuan, J., Piacentini, M., Zhivotovsky, B., Melino, G., 2009. Classification of cell death: recommendations of the nomenclature committee on cell death 2009. Cell Death Differ. 16, 3-11.
19. Lasa-Saracibar, B., Estella-Hermoso de Mendoza, A., Guada, M., Dios-Vieitez, C., Blanco-Prieto, M.J., 2012. Lipid nanoparticles for cancer therapy: state of the art and future prospects. Expert Opin. Drug Deliv. 9, 1245-1261.
20. Lasa-Saracibar, B., Mendoza, A.E., Mollinedo, F., Odero, M.D., Blanco-Prieto, M.J., 2013. Edelfosine lipid nanosystems overcome drug resistance in leukemic cell lines. Cancer Lett., http://dx.doi.org/10.1016/j.canlet.2013. 01.018 (in press), [Epub ahead of print].
21. Lu, X., Kang, Y., 2007. Organotropism of breast cancer metastasis. J. Mammary Gland Biol. Neoplasia 12, 153-162. (Pubitemid 47215433)
22. Mollinedo, F., de la Iglesia-Vicente, J., Gajate, C., Estella-Hermoso de Mendoza, A., Villa-Pulgarin, J.A., Campanero, M.A., Blanco-Prieto, M.J., 2010a. Lipid rafttargeted therapy in multiple myeloma. Oncogene 29, 3748-3757.
23. Mollinedo, F., de la Iglesia-Vicente, J., Gajate, C., Estella-Hermoso de Mendoza, A., Villa-Pulgarin, J.A., de Frias, M., Roue, G., Gil, J., Colomer, D., Campanero, M.A., Blanco-Prieto, M.J., 2010b. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin. Cancer Res. 16, 2046-2054.
24. Mollinedo, F., Gajate, C., Martin-Santamaria, S., Gago, F., 2004. ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor. Curr. Med. Chem. 11, 3163-3184. (Pubitemid 39539180)
25. Müller, R.H., 1996. Zetapotential und Partikelladung in der Laborpraxis- Einführung in die Theorie, praktische Meßdurchfü hrung. Dateninterpretation. Wissenschaftliche, Verlagsgesellschaft, Stuttgart, pp. 37.
26. Munder, P.G., Westphal, O., 1990. Antitumoral and other biomedical activities of synthetic ether lysophospholipids. Chem. Immunol. 49, 206-235.
27. Na, H.K., Surh, Y.J., 2008. The antitumor ether lipid edelfosine (ET-18-O-CH3) induces apoptosis in H-ras transformed human breast epithelial cells: by blocking ERK1/2 and p38 mitogen-activated protein kinases as potential targets. Asia Pac. J. Clin. Nutr. 17, 204-207.
28. Nieto-Miguel, T., Fonteriz, R.I., Vay, L., Gajate, C., Lopez-Hernandez, S., Mollinedo, F., 2007. Endoplasmic reticulum stress in the proapoptotic action of edelfosine in solid tumor cells. Cancer Res. 67, 10368-10378. (Pubitemid 350070812)
29. Peer, D., Karp, J.M., Hong, S., Farokhzad, O.C., Margalit, R., Langer, R., 2007. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751-760. (Pubitemid 350223348)
30. Pushkareva, M.Y., Janoff, A.S., Mayhew, E., 1999. Inhibition of cell division but not nuclear division by 1-O-octadecyl-2-O-methyl-Sn-glycero-3- phosphocholine. Cell Biol. Int. 23, 817-828. (Pubitemid 30223907)
31. Riccardi, C., Nicoletti, I., 2006. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat. Protoc. 1, 1458-1461.
32. Shafer, S.H., Williams, C.L., 2003. Non-small and small cell lung carcinoma cell lines exhibit cell type-specific sensitivity to edelfosine-induced cell death and different cell line-specific responses to edelfosine treatment. Int. J. Oncol. 23, 389-400.
33. Siegel, R., Naishadham, D., Jemal, A., 2013. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30.
34. Torchilin, V., 2011. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 63, 131-135.
35. Van Blitterswijk, W.J., Verheij, M., 2008. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr. Pharm. Des. 14, 2061-2074.
36. Van der Luit, A.H., Vink, S.R., Klarenbeek, J.B., Perrissoud, D., Solary, E., Verheij, M., van Blitterswijk, W.J., 2007. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol. Cancer Ther. 6, 2337-2345. (Pubitemid 47294762)
37. Varshosaz, J., Minayian, M., Moazen, E., 2010. Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. J. Liposome Res. 20, 115-123.
38. Wagner, B.A., Buettner, G.R., Oberley, L.W., Burns, C.P., 1998. Sensitivity of K562 and HL-60 cells to edelfosine, an ether lipid drug, correlates with production of reactive oxygen species. Cancer Res. 58, 2809-2816. (Pubitemid 28311912)
39. Weigelt, B., Reis-Filho, J.S., 2009. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat. Rev. Clin. Oncol. 6, 718-730.
40. Wellings, S.R., Jensen, H.M., 1973. On the origin and progression of ductal carcinoma in the human breast. J. Natl. Cancer Inst. 50, 1111-1118.
41. Wellings, S.R., Jensen, H.M., Marcum, R.G., 1975. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J. Natl. Cancer Inst. 55, 231-273.
42. Zimmermann, E., Muller, R.H., Mader, K., 2000. Influence of different parameters on reconstitution of lyophilized SLN. Int. J. Pharm. 196, 211-213.